Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community

PharmacoEconomics

Volumn 34, Issue 3, 2016, Pages 227-244

  Ultsch, Bernhard ^a   Damm, Oliver ^b   Beutels, Philippe ^c   Bilcke, Joke ^c   Brüggenjürgen, Bernd ^d   Gerber Grote, Andreas ^e   Greiner, Wolfgang ^b   Hanquet, Germaine ^f   Hutubessy, Raymond ^g   Jit, Mark ^h,i   Knol, Mirjam ^j   von Kries, Rüdiger ^k   Kuhlmann, Alexander ^l   Levy Bruhl, Daniel ^m   Perleth, Matthias ⁿ   Postma, Maarten ^o   Salo, Heini ^p   Siebert, Uwe ^q,r   Wasem, Jürgen ^s   Wichmann, Ole ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

^b BIELEFELD UNIVERSITY   (Germany)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d STEINBEIS UNIVERSITY BERLIN   (Germany)

^e INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE IQWIG   (Germany)

^f BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

^g WORLD HEALTH ORGANIZATION   (Switzerland)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

ⁱ PUBLIC HEALTH ENGLAND   (United Kingdom)

^j NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^k UNIVERSITY OF MUNICH   (Germany)

^l LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^m INSTITUT DE VEILLE SANITAIRE   (France)

ⁿ Joint Committee (G BA)   (Germany)

^o UNIVERSITY OF GRONINGEN   (Netherlands)

^p NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^q UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^r Oncotyrol Center for Personalized Cancer Medicine   (Austria)

^s UNIVERSITY OF DUISBURG ESSEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

ARTICLE; CONSENSUS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION MAKING; ECONOMIC EVALUATION; EUROPE; HEALTH CARE SYSTEM; HEALTH ECONOMIC EVALUATION; IMMUNIZATION; INFECTION PREVENTION; MATHEMATICAL MODEL; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REIMBURSEMENT; UNCERTAINTY; WORKSHOP; CONSENSUS DEVELOPMENT; ECONOMIC MODEL; ECONOMICS; HUMAN; PROCEDURES; STANDARDS;

COST-BENEFIT ANALYSIS; DECISION MAKING; EUROPE; HUMANS; IMMUNIZATION; MODELS, ECONOMIC; VACCINES;

EID: 84959135193     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-015-0335-2     Document Type: Article

References (120)

1. HAS. Choice in methods for Economic Evaluation. 2012. http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-10/choices_in_methods_for_economic_evaluation.pdf. Accessed 18 Dec 2012.
2. KCE. Belgian guidelines for economic evaluations and budget impact analyses: second edition. 2012. https://kce.fgov.be/publication/report/belgian-guidelines-for-economic-evaluations-and-budget-impact-analyses-second-edi#.U9tRNhBtRfY. Accessed 1 Aug 2014.
3. IQWiG. Allgemeine Methoden zur Bewertung von Verhältnissen zwischen Nutzen und Kosten. 2009. https://www.iqwig.de/download/Methodik_fuer_die_Bewertung_von_Verhaeltnissen_zwischen_Kosten_und_Nutzen.pdf. Accessed 16 Sept 2013.
4. WHO. WHO guide for standardization of economic evaluations of immunization programmes. Geneva. 2008. http://whqlibdoc.who.int/hq/2008/WHO_IVB_08.14_eng.pdf. Accessed 6 Dec 2010.
5. SMC. Scottish Medicines Consortium: Guidance for Submission. 2012. http://www.scottishmedicines.org.uk/Submission_Process/Submission_Guidance_and_Templates_for_Industry/Templates-Guidance-for-Submission/Templates-Guidance-for-Submission. Accessed 22 Nov 2012.
6. PHAC. Canadian Immunization Guide. Otawa. 2007. http://www.phac-aspc.gc.ca/publicat/cig-gci/p01-02-eng.php. Accessed 27 Nov 2012.
7. NICE. National institution for health and clinical excellence:Guide to the methods of technology appraisal. 2008. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed 22 Nov 2012.
8. ISPOR. ISPOR Good Practices for Outcomes Research Task Forces. 2014. http://www.ispor.org/taskForces/TFindex.asp. Accessed 19 Nov 2014.
9. Nohynek H, Wichmann O, D Ancona F, Gatekeepers VN. National Advisory Groups and their role in immunization policy-making processes in European countries. Clin Microbiol Infect. 2013;19(12):1096–105.
10. Ricciardi GW, Toumi M, Weil-Olivier C, Ruitenberg EJ, Danko D, Duru G, et al. Comparison of NITAG policies and working processes in selected developed countries. Vaccine. 2014. doi:10.1016/j.vaccine.2014.09.023.
11. Takla A, Wichmann O, Carrillo-Santisteve P, Cotter S, Lévy-Bruhl D, Paradowska-Stankiewicz I, et al. Characteristics and practices of National Immunisation Technical Advisory Groups in Europe and potential for collaboration, April 2014. Evaluation (GRADE). 2015;5:6.
12. Bryson M, Duclos P, Jolly A, Bryson J. A systematic review of national immunization policy making processes. Vaccine. 2010;28(Suppl 1):A6–12. doi:10.1016/j.vaccine.2010.02.026.
13. Bryson M, Duclos P, Jolly A, Cakmak N. A global look at national Immunization Technical Advisory Groups. Vaccine. 2010;28(Suppl 1):A13–7. doi:10.1016/j.vaccine.2009.07.089.
14. ISPOR. Pharmacoeconomic Guidelines Around The World. 2015. http://www.ispor.org/peguidelines/index.asp. Accessed 14 Jul 2015.
15. RKI. International workshop on methods for health economic evaluations of vaccines—workshop reader. 2014. http://www.rki.de/DE/Content/Infekt/Impfen/Forschungsprojekte/STEErING-Projekt/IW_Reader.pdf;jsessionid=341320D8E4169CBE30A6938F3D4A4229.2_cid372?__blob=publicationFile. Accessed 14 July 2015.
16. Basta NE, Halloran ME, Matrajt L, Longini IM Jr. Estimating influenza vaccine efficacy from challenge and community-based study data. Am J Epidemiol. 2008;168(12):1343–52. doi:10.1093/aje/kwn259.
17. Bauch CT, Anonychuk AM, Van Effelterre T, Pham BZ, Merid MF. Incorporating herd immunity effects into cohort models of vaccine cost-effectiveness. Med Decis Making. 2009;29(5):557–69.
18. Beutels P, Edmunds WJ, Antoñanzas F, De Wit GA, Evans D, Feilden R, et al. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. PharmacoEconomics. 2002;20(1):1–7.
19. Beutels P, Scuffham PA, MacIntyre CR. Funding of drugs: do vaccines warrant a different approach? Lancet Infectious diseases. 2008;8(11):727–33. doi:10.1016/S1473-3099(08)70258-5.
20. Beutels P, Van Doorslaer E, Van Damme P, Hall J. Methodological issues and new developments in the economic evaluation of vaccines. Expert Rev Vaccines. 2003;2(5):649–60.
21. Black S. The role of health economic analyses in vaccine decision making. Vaccine. 2013;31(51):6046–9.
22. Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decis Making. 2006;26(5):434–46.
23. de Vries R, Kretzschmar M, Schellekens JFP, Versteegh FGA, Westra TA, Roord JJ et al. Cost-effectiveness of adolescent pertussis vaccination for the netherlands: Using an individual-based dynamic model. PLoS One. 2010;5(10):1–11.
24. Debicki D, Ferko N, Demarteau N, Gallivan S, Bauch C, Anonychuk A, et al. Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine. 2008;26(Suppl 5):16–28.
25. Drummond M, Chevat C, Lothgren M. Do we fully understand the economic value of vaccines? Vaccine. 2007;25(32):5945–57. doi:10.1016/j.vaccine.2007.04.070.
26. Duintjer Tebbens RJ, Thompson KM, Hunink MG, Mazzuchi TA, Lewandowski D, Kurowicka D, et al. Uncertainty and sensitivity analyses of a dynamic economic evaluation model for vaccination programs. Med Decis Making. 2008;28(2):182–200.
27. Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med. 1999;18(23):3263–82.
28. Ethgen O, Standaert B. Population- versus cohort-based modelling approaches. PharmacoEconomics. 2012;30(3):171–81. doi:10.2165/11593050-000000000-00000.
29. Halloran ME, Struchiner CJ, Longini IM Jr. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol. 1997;146(10):789–803.
30. Jit M, Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: A primer. PharmacoEconomics. 2011;29(5):371–86.
31. Jit M, Choi YH, Laprise J-F, Boily M-C, Drolet M, Brisson M. Two-dose strategies for human papillomavirus vaccination: How well do they need to protect? Vaccine. 2014. doi:10.1016/j.vaccine.2014.03.098.
32. Kauf TL. Methodological concerns with economic evaluations of meningococcal vaccines. PharmacoEconomics. 2010;28(6):449–61.
33. Kim JJ, Goldie SJ. Health and Economic Implications of HPV Vaccination in the United States. New Engl J Med. 2008;359(8):821–32. doi:10.1056/NEJMsa0707052.
34. Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. PharmacoEconomics. 2008;26(3):191–215.
35. Klock RM, Brouwer WBF, Annemans LJP, Bos JM, Postma MJ. Towards a healthier discount procedure. Expert Rev Pharmacoecon Outcomes Res. 2005;5(1):59–63. doi:10.1586/14737167.5.1.59.
36. Krol M, Brouwer W. How to estimate productivity costs in economic evaluations. PharmacoEconomics. 2014;32(4):335–44.
37. Mauskopf J, Talbird S, Standaert B. Categorization of methods used in cost-effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models. Expert Rev Pharmacoecon Outcomes Res. 2012;12(3):357–71. doi:10.1586/erp.12.11.
38. O’Mahony JF, de Kok IM, van Rosmalen J, Habbema JD, Brouwer W, van Ballegooijen M. Practical implications of differential discounting in cost-effectiveness analyses with varying numbers of cohorts. Value Health. 2011;14(4):438–42.
39. Parouty M, Le H, Krooshof D, Postma M. Differential time preferences for money and quality of life. PharmacoEconomics. 2014;32(4):411–9.
40. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment. Pharmacoeconomics. 2006;24(4):355–71.
41. Phillips KA, Holtgrave DR. Using cost-effectiveness/cost-benefit analysis to allocate health resources: a level playing field for prevention? Am J Prev Med. 1997;13(1):18–25.
42. Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, Edmunds J, et al. Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-5. Med Decis Making. 2012;32(5):712–21. doi:10.1177/0272989X12454578.
43. Poletti P, Melegaro A, Ajelli M, Del Fava E, Guzzetta G, Faustini L, et al. Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries. PLoS One. 2013;8(4):e60732. doi:10.1371/journal.pone.0060732.
44. Postma MJ. Public health economics of vaccines in the Netherlands: methodological issues and applications. J Public Health. 2008;16(4):267–73.
45. Postma MJ, Westra TA, Quilici S, Largeron N. Economic evaluation of vaccines: specificities and future challenges illustrated by recent European examples. Expert Rev Vaccines. 2013;12(5):555–65.
46. Pradas-Velasco R, Antoñanzas-Villar F, Martínez-Zárate MP. Dynamic modelling of infectious diseases: an application to the economic evaluation of influenza vaccination. PharmacoEconomics. 2008;26(1):45–56.
47. Standaert B, Demarteau N, Talbird S, Mauskopf J. Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models? Vaccine. 2010;28(Suppl 6):G30–8. doi:10.1016/j.vaccine.2010.06.015.
48. Szucs TD. Health economic research on vaccinations and immunisation practices—an introductory primer. Vaccine. 2005;23(17–18):2095–103.
49. Tasset A, Nguyen VH, Wood S, Amazian K. Discounting: technical issues in economic evaluations of vaccination. Vaccine. 1999;17(SUPPL. 3):75–80.
50. Taylor DC, Pawar V, Kruzikas D, Gilmore KE, Pandya A, Iskandar R, et al. Methods of model calibration: observations from a mathematical model of cervical cancer. Pharmacoeconomics. 2010;28(11):995–1000. doi:10.2165/11538660-000000000-00000.
51. Taylor DC, Pawar V, Kruzikas DT, Gilmore KE, Sanon M, Weinstein MC. Incorporating calibrated model parameters into sensitivity analyses: deterministic and probabilistic approaches. PharmacoEconomics. 2012;30(2):119–26.
52. Van de Velde N, Brisson M, Boily MC. Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis. Vaccine. 2010;28(33):5473–84. doi:10.1016/j.vaccine.2010.05.056.
53. Vanni T, Karnon J, Madan J, White RG, Edmunds WJ, Foss AM, et al. Calibrating models in economic evaluation. Pharmacoeconomics. 2011;29(1):35–49.
54. Walker DG, Hutubessy R, Beutels P. WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine. 2010;28(11):2356–9. doi:10.1016/j.vaccine.2009.06.035.
55. Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. PharmacoEconomics. 2006;24(11):1043–53.
56. West RR. Economic rate of discount and estimating cost benefit of viral immunisation programmes. Rev Med Virol. 1999;9(1):51–5.
57. Westra TA, Parouty M, Brouwer WB, Beutels PH, Rogoza RM, Rozenbaum MH, et al. On discounting of health gains from human papillomavirus vaccination: effects of different approaches. Value Health. 2012;15(3):562–7.
58. Ahmed F, Temte JL, Campos-Outcalt D, Schünemann HJ, Group AEBRW. Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the US Centers for Disease Control and Prevention (CDC). Vaccine. 2011;29(49):9171–6.
59. Burchett HE, Mounier-Jack S, Griffiths UK, Mills AJ. National decision-making on adopting new vaccines: a systematic review. Health Policy Plan. 2012;27(Suppl 2):62–76.
60. Dempsey AF, Cowan AE, Stokley S, Messonnier M, Clark SJ, Davis MM. The role of economic information in decision-making by the Advisory Committee on Immunization Practices. Vaccine. 2008;26(42):5389–92.
61. Drummond M. Funding processes for new vaccines: The need for greater understanding of the economic issues. J Public Health. 2008;16(4):261–5.
62. Erickson LJ, De Wals P, Farand L. An analytical framework for immunization programs in Canada. Vaccine. 2005;23(19):2470–6. doi:10.1016/j.vaccine.2004.10.029.
63. Farrant A. The fair innings argument and increasing life spans. J Med Ethics. 2009;35(1):53–6. doi:10.1136/jme.2007.023762.
64. Freed GL. The structure and function of immunization advisory committees in Western Europe. Human Vaccines. 2008;4(4):292–7.
65. Goetghebeur M, Wagner M, Khoury H, Levitt R, Erickson L, Rindress D. Evidence and value: impact on DEcisionMaking—the EVIDEM framework and potential applications. BMC Health Serv Res. 2008;8(1):270.
66. Hall AJ. The United Kingdom Joint Committee on vaccination and immunisation. Vaccine. 2010;28(Suppl 1):54–7.
67. Houweling H, Verweij M, Ruitenberg EJ. National Immunisation Programme Review Committee of the Health Council of the N. Criteria for inclusion of vaccinations in public programmes. Vaccine. 2010;28(17):2924–31.
68. Hutubessy R, Henao AM, Namgyal P, Moorthy V, Hombach J. Results from evaluations of models and cost-effectiveness tools to support introduction decisions for new vaccines need critical appraisal. BMC Med. 2011;9:55.
69. Ismail SJ, Langley JM, Harris TM, Warshawsky BF, Desai S, FarhangMehr M. Canada’s National Advisory Committee on Immunization (NACI): evidence-based decision-making on vaccines and immunization. Vaccine. 2010;28(Suppl 1):58–63.
70. Jacobs P. Are economic evaluations an important tool in vaccine policy decisions? Expert Rev Pharmacoecon Outcomes Res. 2011;11(5):507–11.
71. Caro J, Eddy DM, Kan H, Kaltz C, Patel B, Eldessouki R, et al. Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force Report. Value Health. 2014;17(2):174–82.
72. Kimman TG, Boot HJ, Berbers GA, Vermeer-de Bondt PE, Ardine de Wit G, de Melker HE. Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs. Vaccine. 2006;24(22):4769–78.
73. Newall AT, Reyes JF, Wood JG, McIntyre P, Menzies R, Beutels P. Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses. Vaccine. 2014;32(7):759–65.
74. Nohynek H. The Finnish decision-making process to recommend a new vaccine: from vaccine research to vaccination policy. J Public Health. 2008;16(4):275–80.
75. Piso B, Wild C. Decision support in vaccination policies. Vaccine. 2009;27(43):5923–8. doi:10.1016/j.vaccine.2009.07.105.
76. Piso B, Zechmeister I, Geiger-Gritsch S. Criteria for vaccine introduction: results of a DELPHI discussion among international immunisation experts on a stepwise decision-making procedure. J Public Health. 2011;19(1):73–80.
77. Spicher VM. The Federal Vaccination Commission in Switzerland: an officially appointed independent commission ensuring evidence-based recommendations and transparent procedures. Vaccine. 2010;28(Suppl 1):48–53.
78. Thokala P, Duenas A. Multiple Criteria decision analysis for health technology assessment. Value Health. 2012;15(8):1172–81. doi:10.1016/j.jval.2012.06.015.
79. Welte R, Trotter CL, Edmunds WJ, Postma MJ, Beutels P. The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine. PharmacoEconomics. 2005;23(9):855–74.
80. Williams A. Intergenerational equity: an exploration of the ‘fair innings’ argument. Health Econ. 1997;6(2):117–32. doi:10.1002/(SICI)1099-1050(199703)6:2<117:AID-HEC256>3.0.CO;2-B.
81. Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Value Health. 2012;15(6):812–20. doi:10.1016/j.jval.2012.06.014.
82. Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15(12):1295–310.
83. Willem L, Stijven S, Vladislavleva E, Broeckhove J, Beutels P, Hens N. Active learning to understand infectious disease models and improve policy making. PLoS Comput Biol. 2014;10(4):e1003563.
84. Zechmeister I, Blasio BFd, Garnett G, Neilson AR, Siebert U. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine. 2009;27(37):5133–41. doi:10.1016/j.vaccine.2009.06.039.
85. Baguelin M, Jit M, Miller E, Edmunds WJ. Health and economic impact of the seasonal influenza vaccination programme in England. Vaccine. 2012;30(23):3459–62. doi:10.1016/j.vaccine.2012.03.019.
86. V Barnabas R, Kulasingam SL. Economic evaluations of human papillomavirus vaccines. Expert Rev Pharmacoecon Outcomes Res. 2007;7(3):251–67. doi:10.1586/14737167.7.3.251.
87. Bilcke J, Beutels P, Brisson M, Jit M. Accounting for methodological, structural, and parameter uncertainty in decision-analytic models: a practical guide. Med Decis Making. 2011;31(4):675–92. doi:10.1177/0272989x11409240.
88. Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis. 2007;44(10):1280–8. doi:10.1086/514342.
89. Brisson M, Pellissier JM, Levin MJ. Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia. Clin Infect Dis. 2007;45(11):1527–9. doi:10.1086/523011.
90. Brisson M, Pellissier JM, Camden S, Quach C, De Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Human Vaccines. 2008;4(3):238–45.
91. McLean AR, Blower SM. Modelling HIV vaccination. Trends Microbiol. 1995;3(12):458–63. doi:10.1016/S0966-842X(00)89010-1.
92. Metcalf CJE, Andreasen V, Bjørnstad ON, Eames K, Edmunds WJ, Funk S, et al. Seven challenges in modeling vaccine preventable diseases. Epidemics. 2015;10:11–5. doi:10.1016/j.epidem.2014.08.004.
93. Weidemann F, Dehnert M, Koch J, Wichmann O, Hohle M. Modelling the epidemiological impact of rotavirus vaccination in Germany—a Bayesian approach. Vaccine. 2014;32(40):5250–7. doi:10.1016/j.vaccine.2014.06.090.
94. Ultsch B, Weidemann F, Reinhold T, Siedler A, Krause G, Wichmann O. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. BMC Health Serv Res. 2013;13(1):359.
95. Seto K, Marra F, Raymakers A, Marra CA. The cost effectiveness of human papillomavirus vaccines: a systematic review. Drugs. 2012;72(5):715–43. doi:10.2165/11599470-000000000-00000.
96. van Hoek AJ, Choi YH, Trotter C, Miller E, Jit M. The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England. Vaccine. 2012. doi:10.1016/j.vaccine.2012.10.017.
97. Brisson M, Edmunds W. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making. 2003;23(1):76–82.
98. Brisson M, Edmunds WJ. The cost-effectiveness of varicella vaccination in Canada. Vaccine. 2002;20(7–8):1113–25.
99. van Hoek AJ, Andrews N, Campbell H, Amirthalingam G, Edmunds WJ, Miller E. The social life of infants in the context of infectious disease transmission; social contacts and mixing patterns of the very young. PloS One. 2013;8(10):e76180. doi:10.1371/journal.pone.0076180.
100. Fumanelli L, Ajelli M, Manfredi P, Vespignani A, Merler S. Inferring the structure of social contacts from demographic data in the analysis of infectious diseases spread. PLoS Comput Biol. 2012;8(9):e1002673. doi:10.1371/journal.pcbi.1002673.
101. Poletti P, Melegaro A, Ajelli M, del Fava E, Guzzetta G, Faustini L et al. Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three european countries. PLoS One. 2013;8(4):1–13.
102. Nelder JA, Mead R. A simplex method for function minimization. Comput J. 1965;7(4):308–13. doi:10.1093/comjnl/7.4.308.
103. Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, et al. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol. 2007;166(2):137–50. doi:10.1093/aje/kwm086.
104. Basu S, Galvani AP. Re: “Multiparameter calibration of a natural history model of cervical cancer”. Am J Epidemiol. 2007;166(8):983. doi:10.1093/aje/kwm240(author reply-4).
105. Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB, et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force—7. Value Health. 2012;15(6):843–50. doi:10.1016/j.jval.2012.04.012.
106. Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—modeling studies. Value Health. 2003;6(1):9–17.
107. Stout NK, Knudsen AB, Kong CY, McMahon PM, Gazelle GS. Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics. 2009;27(7):533–45.
108. Jackson CH, Sharples LD, Thompson SG. Structural and parameter uncertainty in Bayesian cost-effectiveness models. J R Stat Soc Ser C Appl Stat. 2010;59(2):233–53. doi:10.1111/j.1467-9876.2009.00684.x.
109. Jackson CH, Thompson SG, Sharples LD. Accounting for uncertainty in health economic decision models by using model averaging. J R Stat Soc Ser A. 2009;172(2):383–404. doi:10.1111/j.1467-985X.2008.00573.x.
110. Jackson CH, Bojke L, Thompson SG, Claxton K, Sharples LD. A framework for addressing structural uncertainty in decision models. Med Decis Making. 2011;31(4):662–74. doi:10.1177/0272989X11406986.
111. Christensen H, Hickman M, Edmunds WJ, Trotter CL. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine. 2013;31(23):2638–46. doi:10.1016/j.vaccine.2013.03.034.
112. Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Value Health. 2012;15(6):835–42. doi:10.1016/j.jval.2012.04.014.
113. Skoupá J, Annemans L, Hájek P. Health economic data requirements and availability in the european union: results of a survey among 10 European countries. Value Health Reg Issues. 2014;4:53–7.
114. Jit M, Mibei W. Discounting in the evaluation of the cost-effectiveness of a vaccination programme: A critical review. Vaccine. 2015;33(32):3788–94. doi:10.1016/j.vaccine.2015.06.084.
115. Bos JM, Beutels P, Annemans L, Postma MJ. Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases. PharmacoEconomics. 2004;22(18):1171–9.
116. Weinke T, Glogger A, Bertrand I, Lukas K. The societal impact of herpes zoster and postherpetic neuralgia on patients, life partners, and children of patients in Germany. Sci World J. 2014;2014:749698. doi:10.1155/2014/749698.
117. Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med. 2006;145(5):317–25.
118. Damm O, Ultsch B, Horn J, Mikolajczyk R, Greiner W, Wichmann O. Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries. BMC Public Health. 2015;15(1):1–19. doi:10.1186/s12889-015-1861-8.
119. Annemans L, Bresse X, Gobbo C, Papageorgiou M. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J Med Econ. 2010;13(3):537–51.
120. Szucs TD, Kressig RW, Papageorgiou M, Kempf W, Michel JP, Fendl A, et al. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccines. 2011;7(7):749–56. doi:10.4161/hv.7.7.15573.